BRIEF-Cynata Therapeutics initiates formal regulatory engagement for U.S. market

* Cynata expects to receive FDA's written advice arising from pre-ind meeting by July 2017.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.